Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone and vascular effects of magnesium supplements in CKD patients (the MagicalBone Pilot Study).
Pendón-Ruiz de Mier MV, Santamaría R, Moyano-Peregrín C, Gordillo JE, Salmoral-Chamizo A, López-López I, Rodelo-Haad C, Valle C, Membrives-González C, López-Ruiz DJ, Álvarez-Benito M, López-Baltanás R, Torralbo AI, Valdés-Díaz KC, García-Sáez RM, Jurado-Montoya D, Pinaglia-Tobaruela G, Martínez-Moreno JM, Martín-Malo A, Soriano S, Rodríguez M, Rodríguez-Ortiz ME, Muñoz-Castañeda JR. Pendón-Ruiz de Mier MV, et al. Among authors: lopez lopez i. Nefrologia (Engl Ed). 2024 Sep-Oct;44(5):721-730. doi: 10.1016/j.nefroe.2024.11.001. Nefrologia (Engl Ed). 2024. PMID: 39547778 Free article. Clinical Trial.
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D; Cemdisiran Phase 2 Study Investigators and Collaborators. Barratt J, et al. Clin J Am Soc Nephrol. 2024 Apr 1;19(4):452-462. doi: 10.2215/CJN.0000000000000384. Epub 2024 Jan 15. Clin J Am Soc Nephrol. 2024. PMID: 38214599 Clinical Trial.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
[Update on Duchenne muscular dystrophy].
Leiva-Cepas F, Montaño Martínez A, López-López I. Leiva-Cepas F, et al. Among authors: lopez lopez i. Semergen. 2021 Oct;47(7):472-481. doi: 10.1016/j.semerg.2021.06.008. Epub 2021 Aug 18. Semergen. 2021. PMID: 34417099 Spanish.
Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study.
Martin-Moreno PL, Sánchez-Fructuoso AI, Mazuecos A, Mir M, Lopez-Lopez I, González-Rinne A, Coca A, Valero R, Ventura Galiano A, Ridao N, Toapanta-Gaibor NG, Fernández-Tagarro E, Cruzado-Vega L, Pérez-Mir M, Jiménez C. Martin-Moreno PL, et al. Among authors: lopez lopez i. Clin Transplant. 2021 May;35(5):e14256. doi: 10.1111/ctr.14256. Epub 2021 Feb 27. Clin Transplant. 2021. PMID: 33599030
32 results